ROIVHIGH SIGNALFINANCIAL10-K

ROIV experienced a dramatic revenue decline alongside substantial reductions in cash position and total liabilities, suggesting a major business restructuring or divestiture.

The company's revenue fell substantially while maintaining elevated SG&A expenses, indicating operational challenges or a significant change in business model. The concurrent reduction in both cash reserves (from $6.5B to $2.7B) and total liabilities (from $774M to $250M) suggests a major transaction or restructuring occurred during the period.

Comparing 2025-05-29 vs 2024-05-30View on EDGAR →
FINANCIAL ANALYSIS

ROIV's financial profile changed dramatically, with revenue declining substantially while operating expenses remained elevated, creating pressure on profitability. The balance sheet contracted significantly with cash reserves falling by $3.8 billion and total liabilities decreasing by over $500 million, indicating either major capital returns to shareholders, debt settlements, or business divestitures. Despite the cash reduction, the company maintains a strong balance sheet with $2.7 billion in cash and reduced debt obligations.

FINANCIAL STATEMENT CHANGES
Revenue
P&L
-76.7%
$124.8M$29.1M

Revenue declined 76.7% — significant demand weakness or market share loss warrants investigation.

Total Liabilities
Balance Sheet
-67.7%
$774.0M$249.7M

Liabilities reduced 67.7% — deleveraging improves balance sheet strength and financial flexibility.

Cash & Equivalents
Balance Sheet
-58.5%
$6.5B$2.7B

Cash declined 58.5% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Current Liabilities
Balance Sheet
-44%
$266.8M$149.4M

Current liabilities reduced — improved short-term financial position and working capital health.

Current Assets
Balance Sheet
-25.7%
$6.7B$5.0B

Current assets declined 25.7% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-24.7%
$7.2B$5.4B

Total assets contracted 24.7% — asset sales, write-downs, or balance sheet optimization underway.

Interest Expense
P&L
+24.3%
$28.0M$34.8M

Interest costs rose 24.3% — monitor debt levels and coverage ratio in rising rate environment.

Stockholders Equity
Balance Sheet
-21.5%
$6.0B$4.7B

Equity decreased 21.5% — buybacks or losses reducing book value, monitor solvency ratios.

Total Debt
Balance Sheet
+14.7%
$375.5M$430.6M

Debt rose 14.7% — additional borrowing for investment or operations; monitor coverage ratios.

SG&A Expense
P&L
+14.5%
$600.5M$687.4M

SG&A increased modestly — likely reflects growth-related hiring or sales expansion investment.

LANGUAGE CHANGES
NEW — 2025-05-29
PRIOR — 2024-05-30
ADDED
As of May 21, 2025 there were 679,806,070 common shares outstanding.
We will likely incur significant operating losses for the foreseeable future and may never achieve sustained profitability.
We face risks associated with acquisitions, divestitures and other strategic transactions.
We face risks associated with the use of our cash, cash equivalents and marketable securities.
We are exposed to risks related to our significant holdings of cash, cash equivalents and marketable securities.
+7 more — sign up free →
REMOVED
As of May 28, 2024 there were 738,721,807 common shares outstanding.
We have generated limited revenue from our operations since inception, and there is no guarantee that we will generate significant revenues in the future.
We have relatively limited experience as a commercial-stage company and the marketing and sale of VTAMA (tapinarof) or any future products may be unsuccessful or less successful than anticipated.
Our business is dependent to a significant extent on the successful commercialization of VTAMA and the development, regulatory approval and commercialization of our current and future products and product candidates.
We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →